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Abstract
Non-alcoholic fatty liver disease (NAFLD) parallels the global obesity epidemic with unmet therapeutic needs. We investigated
whether inhibition of hypoxia-inducible factor prolyl 4-hydroxylase-2 (HIF-P4H-2), a key cellular oxygen sensor whose inhi-
bition stabilizes HIF, would protect from NAFLD by subjecting HIF-P4H-2-deficient (Hif-p4h-2gt/gt) mice to a high-fat, high-
fructose (HFHF) or high-fat, methionine-choline-deficient (HF-MCD) diet. On both diets, the Hif-p4h-2gt/gt mice gained less
weight and had less white adipose tissue (WAT) and its inflammation, lower serum cholesterol levels, and lighter livers with less
steatosis and lower serum ALT levels than the wild type (WT). The intake of fructose in majority of the Hif-p4h-2gt/gt tissues,
including the liver, was 15–35% less than in the WT. We found upregulation of the key fructose transporter and metabolizing
enzyme mRNAs, Slc2a2, Khka, and Khkc, and higher ketohexokinase activity in the Hif-p4h-2gt/gt small intestine relative to the
WT, suggesting enhanced metabolism of fructose in the former. On the HF-MCD diet, the Hif-p4h-2gt/gt mice showed more
browning of the WATand increased thermogenesis. A pharmacological pan-HIF-P4H inhibitor protected WTmice on both diets
against obesity, metabolic dysfunction, and liver damage. These data suggest that HIF-P4H-2 inhibition could be studied as a
novel, comprehensive treatment strategy for NAFLD.
Key messages
• HIF-P4H-2 inhibition enhances intestinal fructose metabolism protecting the liver.
• HIF-P4H-2 inhibition downregulates hepatic lipogenesis.
• Induced browning of WAT and increased thermogenesis can also mediate protection.
• HIF-P4H-2 inhibition offers a novel, comprehensive treatment strategy for NAFLD.
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Introduction
The prevalence of non-alcoholic fatty liver disease (NAFLD)
is constantly increasing, currently affecting a quarter of people
worldwide [1]. It is considered the hepatic manifestation of
metabolic syndrome, strongly linked to obesity and insulin
resistance (IR), which further predisposes for diabetes and
cardiovascular diseases [2]. NAFLD is characterized by he-
patic triglyceride accumulation and if untreated, can lead to
steatohepatitis (NASH), cirrhosis, and hepatocellular carcino-
ma (HCC) [1]. Western diet, rich in saturated fat and carbo-
hydrates, especially fructose, is considered to be one of the
major causes of the NAFLD epidemic [3]. No effective cure is
currently available [4].
A decrease in oxygen availability activates a survival
mechanism called the hypoxia response [5–7]. Hypoxia-
inducible factor (HIF) functions as the major regulator of
oxygen homeostasis, and HIF prolyl 4-hydroxylases (HIF-
P4Hs/PHDs/EglNs), especially HIF-P4H-2, are oxygen
sensors that target HIFα for degradation under normoxia
[5, 8]. Under hypoxia, the oxygen-dependent hydroxyl-
ation is compromised [9], allowing HIF to form a tran-
scriptionally active αβ-dimer and upregulate > 300 genes.
These genes increase oxygen availability by inducing
erythropoiesis and angiogenesis, and also reduce its de-
mand via regulation of energy metabolism by reducing
oxidative phosphorylation and inducing non-oxygen-
demanding glycolysis [5–7].
The first-in-class small-molecule HIF-P4H inhibitor
that activates the hypoxia response has been approved
for treatment of renal anemia and several others are in
clinical trials [10, 11]. Recent data suggest that besides
anemia, HIF-P4H inhibition and hypoxia are powerful
tools for promoting metabolic health [10, 12–17]. We
have previously shown that genetic HIF-P4H-2 deficiency
protects the Hif-p4h-2gt/gt mice against metabolic
disorder–related hepatic steatosis and chemically induced
HCC [14, 18], and against alcoholic liver disease (ALD)
by downregulating hepatic lipogenesis and improving the
elimination of harmful ethanol metabolites and reactive
oxygen species [19]. Treatment of wild-type (WT) mice
with a pan-HIF-P4H inhibitor FG-4497 phenocopied the
protection against ALD [19]. However, the role of HIF-
P4H-2 in NAFLD has not been studied systemically be-
fore. We therefore subjected the Hif-p4h-2gt/gt mice, and
FG-4497-treated WT mice, to two diet-induced rodent
NAFLD models: a high-fat, high-fructose (HFHF) diet
[20] and a methionine-choline-deficient high-fat diet
(HF-MCD) [21] that mimic the human disease. The HF-
MCD can additionally lead to NASH [22]. Our data show
significantly less steatosis and liver damage in the Hif-
p4h-2gt/gt mice compared with the WT. Treatment with
FG-4497 phenocopied most of these effects.
Materials and methods
Animal experiments
Animal experiments were performed according to protocols
approved by the National Animal Experiment Board of
Finland (ESAVI-6154, ESAVI-8179). Hif-p4h-2gt/gt mice
were generated as previously described [23]. Five-month-old
Hif-p4h-2gt/gt and WT males were fed a 30% (w/v) fructose
solution for drinking water combined with a high-fat, modi-
fied Surwit diet with added cholesterol (HFHF diet,
D09061703, 58% kcal fat) for 8 weeks. Six-month-old and
2-month-old Hif-p4h-2gt/gt and WT females were fed a high-
fat, choline-deficient diet with 0.1% methionine (HF-MCD
diet, A06071309, 45% kcal fat) for 7 weeks, and the 2-
month-old mice were studied with an automated home cage
phenotyping system (PhenoMaster, TSE Systems) for the last
week. For the pharmacological studies, 8-month-old WT fe-
males (Hif-p4h-2gt/gt littermates) were fed the HFHF diet for
6 weeks and 4-month-old WT females (C57BL/6JRccHsd,
Envigo) the HF-MCD diet for 3 weeks and given thrice a
week orally 60 mg/kg FG-4497 (FibroGen, Inc., USA) or
vehicle.
Further methods are described in the supplementary
material.
Results
HIF-P4H-2-deficient mice were protected
from fructose diet–induced weight gain, but the diet
did not induce NAFLD
Hif-p4h-2gt/gt mice and their WT littermates were fed a
standard rodent diet with a 30% fructose solution for
16 weeks. Although the daily intake of the fructose solu-
tion was similar between the genotypes (Fig. S1a), the
Hif-p4h-2gt/gt mice had a ~ 20% lower body weight than
the WT at sacrifice, had gained less weight during the
diet, and had > 50% less gonadal white adipose tissue
(WAT) (Fig. S1b–d). The Hif-p4h-2gt/gt mice also showed
a slight trend towards better glucose tolerance compared
with the WT (Fig. S1e). The Hif-p4h-2gt/gt livers were
21% lighter than the WT livers (Fig. S1f), suggesting
more fructose-induced hepatic steatosis in the WT, since
no baseline difference exits between the genotypes [14].
However, the diet only induced visible steatosis and in-
creased the serum alanine aminotransferase (ALT) levels
in a few WT mice, and no liver inflammation in either
genotype (Fig. S1g–i), thus not being potent enough to
induce NAFLD. Hence, we next combined the 30% fruc-
tose solution with a high-fat diet (HFHF) to better mimic
Western diet.
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HIF-P4H-2-deficient mice were protected
from obesity and retained a healthier serum lipid
profile than the WT on a HFHF diet
The Hif-p4h-2gt/gt and WT mice were fed the HFHF diet for
8 weeks, during which the former did not gain any weight,
whereas the latter’s bodyweight increased by ~ 10%, resulting
in an almost 30% higher body weight at sacrifice (Fig. 1a–c).
Consistently with this, the Hif-p4h-2gt/gt mice had 40% less
WAT and also less brown adipose tissue (BAT) than the WT
(Fig. 1d, e), as well as smaller adipocytes (Fig. 1f).
Additionally, the Hif-p4h-2gt/gt mice had less inflammatory
macrophage aggregates in their WAT than the WT (Fig. 1g),
and furthermore, their serum leptin levels were lower
(Fig. 1h). The HFHF diet induced elevation of the serum total
cholesterol, HDL, and LDL levels in the WT, which the Hif-
p4h-2gt/gtmice were protected against (Fig. 1i). There were no
differences in serum triglyceride and free fatty acid (FFA)
levels between the genotypes (Fig. 1j).
Hif-p4h-2gt/gt mice were protected against HFHF
diet–induced steatosis and liver damage
After the 8-week HFHF diet, the WT liver weights were sig-
nificantly ~ 16% higher than the Hif-p4h-2gt/gt (Fig. 2a), and
consistently, the hepatic triglyceride content of the Hif-p4h-
2gt/gt livers was > 40% less than that of the WT (Fig. 2b).
Histological evaluation demonstrated that 50% of the Hif-
p4h-2gt/gt livers had no steatosis, compared with 33% of the
WT, while severe steatosis was observed in > 30% of the WT,
but only 10% of the Hif-p4h-2gt/gt livers (Fig. 2c). The HFHF
diet also induced mild inflammation and fibrosis in ~ 30% of
theWT livers but not theHif-p4h-2gt/gt (Fig. 2d, e). The serum
ALT levels in the Hif-p4h-2gt/gt mice were slightly above the
physiological limit (55 IU/L) whereas theWTs were at a path-
ological level of 107 IU/L (Fig. 2f). Similar trend was ob-
served in the serum aspartate aminotransferase (AST) levels
(Fig. 2g). Additionally, lower levels of hepatic acetyl-CoA,
lipid, and cholesterol biosynthesis precursor were observed
in the Hif-p4h-2gt/gt livers than in the WT (Fig. 2h). In agree-
ment, many hepatic lipid metabolism mRNAs were downreg-
ulated in the Hif-p4h-2gt/gt livers compared with those in WT.
These included the key regulators of glucose metabolism and
lipid synthesis, the glucose-activated Chrebp and the insulin-
activated Srebf1c, and their target genes Fasn, Scd1, and
Gpam; the master regulators of hepatic lipid metabolism
Ppara and Pparg along with their target genes Acsl1, Dgat1,
Pnpla2, Pnpla3, Mttp, and Cd36; and the lipogenesis, fatty
acid (FA) oxidation, and cholesterol metabolism mRNAs
Lpin1, Lpin2, Cyp2e1, Ldlr, Hmgcr, and Hmgcs (Fig. 2i).
Furthermore, the inflammation and fibrosis markers Cd68,
F4/80, Tgfb1,Mmp9, and Acta2 (α-sma) were downregulated,
corresponding to the histological findings, as was Gpx1,
whose downregulation in mouse liver improves glucose me-
tabolism and reduces steatohepatitis (Fig. 2i) [24, 25]. In
agreement, a 30% decrease was observed in the protein levels
Fig. 1 HIF-P4H-2-deficient mice are protected against high-fat, high-
fructose (HFHF) diet–induced obesity, adipose tissue inflammation, and
high cholesterol levels. Wild-type (wt) and Hif-p4h-2gt/gt (gt/gt) males
were studied while on an 8-week HFHF diet (n = 8–10/group). a Body
weight development during the diet. b Body weight at sacrifice. cWeight
gain at the end of the diet relative to weights on the day before the diet
started. d Weight of gonadal WAT. e Weight of BAT. f Cross-sectional
area of WAT adipocytes. Scale bar = 100 μm. g Number of macrophage
aggregates inWAT. h Serum leptin levels. i Serum total cholesterol, HDL
cholesterol, and LDL cholesterol levels. j Serum TG and FFA levels (n =
6–10/group for FFA). Data are means ± SEM. *p < 0.05, **p < 0.01,
***p < 0.001. BAT, brown adipose tissue; FFA, free fatty acids; s, serum;
TG, triglycerides; WAT, white adipose tissue
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of FAS in the Hif-p4h-2gt/gt livers (Fig. 2j). The hepatic Hif-
p4h-2mRNA levels were down to a similar extent (~ 40%) as
reported earlier [14] (Fig. 2i), and the protein levels of HIF-
P4H-2, studied with baseline Hif-p4h-2gt/gt and WT primary
hepatocytes, were correspondingly downregulated (Fig. S2).
Altogether, these data indicate that the Hif-p4h-2gt/gt mice
Fig. 2 HIF-P4H-2 deficiency protects mice from high-fat, high-fructose
(HFHF) diet–induced fatty liver disease. Wild-type (wt) and Hif-p4h-2gt/gt
(gt/gt) males were studied while on an 8-weekHFHF diet (n = 8–10/group).
a Liver weight. b Hepatic triglyceride content. c Scoring of steatosis and
H&E-stained liver sections. Steatosis grading: “None” corresponds to
scores 0–2, “Moderate” to 3, and “Severe” to 4. Images are representative
of scoring for wt. Scale bar = 500 μm for × 4 and 200 μm for × 10. d
Scoring of inflammation from H&E-stained liver sections. “No”
corresponds to score 0 and “Yes” to 1–2. Arrows indicate neutrophil
clusters in wt. Scale bar = 100 μm. e Scoring of fibrosis from Masson’s
trichrome–stained liver sections. “No” corresponds to score 0 and “Yes” to
1–2. Images are representative of scoring for wt. Scale bar = 100 μm. f
Serum ALT levels. g Serum AST levels. h Liver acetyl-CoA levels. i
qPCR analysis of liver mRNA levels of gt/gt mice relative to wt, studied
relative to TATA-box-binding protein mRNA. j Western blotting and
densitometric quantification of hepatic FAS levels (n = 4/group.). Tubulin
was used as a loading control. a, b, f–j Data are means ± SEM. *p ≤ 0.05,
**p < 0.01. ACSL1, acyl-CoA synthetase long-chain family member 1;
ACTA2, actin alpha 2, smooth muscle; ALT, alanine aminotransferase;
AST, aspartate aminotransferase; CHREBP, carbohydrate-responsive
element-binding protein; CYP2E1, cytochrome P450 family-2 subfamily
e member 1; DGAT1, diacylglycerol o-acyltransferase 1; FAS/FASN, fatty
acid synthase; FA, fatty acid; GPAM, mitochondrial glycerol-3-phosphate
acyltransferase; GPX1, glutathione peroxidase 1; HMGCS/HMGCR,
hydroxymethylglutaryl-CoA synthase/reductase; LDLR, low-density
lipoprotein receptor; LPIN, lipin; MMP9, matrix metallopeptidase 9;
MTTP, microsomal triglyceride transfer protein; PNPLA, patatin-like
phospholipase domain containing; PPAR a/g, peroxisome proliferator–
activated receptor alpha/gamma; s, serum; SCD1, stearoyl-CoA
desaturase 1; SREBF1c, sterol regulatory element-binding protein 1c;
TG, triglycerides; TGFb1, transforming growth factor beta 1
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were protected fromHFHF diet–induced metabolic symptoms
of NAFLD, hepatic fat accumulation, and liver damage.
HIF-P4H-2-deficient mice had lower hepatic fructose
levels and better glucose tolerance on the HFHF diet
than the WT
We next studied the 14C-labeled fructose uptake by tissues
15 min after oral administration. Majority of radioactivity was
found in the intestine in both genotypes (Fig. 3a) while no
difference was seen in its secretion to feces or urine between
the genotypes (Fig. S3a). Interestingly, the 14C levels measured
in most tissues were 15–35% lower in the Hif-p4h-2gt/gt mice
than in the WT, the reduction in the liver, kidney, and serum
reaching significance, unlike the induction of ~ 20% in the in-
testine, pancreas, and BAT (Fig. 3a). The sum of radioactivity in
all tissues was similar in both genotypes (Fig. 3b), but the sum
excluding the intestine was significantly lower in the Hif-p4h-
2gt/gt mice, suggesting that the lower amount of fructose found
in the liver, kidney, and serum would correspond to increased
uptake by the Hif-p4h-2gt/gt intestine (Fig. 3a). The small intes-
tine metabolizes most of dietary fructose ketohexokinase
(KHK) dependently, and if its clearance capacity is exceeded
by high fructose concentration, the excess fructose spills over
into the liver and other organs, as reported previously [26].
Therefore, we studied the mRNA levels of KHK isoenzymes
and fructose transporters and found upregulation of Slc2a2
(GLUT2) mRNA levels in the Hif-p4h-2gt/gt small intestine rel-
ative to the WT, the downregulation ofHif-p4h-2mRNA being
~ 65% in the intestine in the former (Fig. 3c). However, no
difference was seen in the immunostaining of GLUT2 (Fig.
S3b). Interestingly, the Khka and Khkc mRNA levels were sig-
nificantly higher in the Hif-p4h-2gt/gt small intestine than in the
WT (Fig. 3c) as was the measured catalytic KHK activity
(Fig. 3d). Altogether, these data suggest enhanced fructose me-
tabolism in the Hif-p4h-2gt/gt intestine, which would result in
less fructose being transported to the liver and other tissues.
Furthermore, the HFHF-fed Hif-p4h-2gt/gt mice maintained a
better glucose tolerance than the WTand had lower serum insu-
lin levels and HOMA-IR scores, indicating better insulin sensi-
tivity (Fig. 3e–g). A similar reduction was seen in circulating
levels of the harmful byproducts of fructose metabolism, uric
acid, and lactate (Fig. 3h, i), supporting differences in its metab-
olism between genotypes. This, and the lower lactate/glucose
ratio in the Hif-p4h-2gt/gt mice (Fig. 3j), agrees with their previ-
ously characterized enhanced lactate clearance [27]. The hepatic
Fig. 3 Changes in fructose metabolism associated with protection from
high-fat, high-fructose (HFHF) diet–induced NAFLD in the HIF-P4H-2-
deficient mice. Wild-type (wt) and Hif-p4h-2gt/gt (gt/gt) males after e–g 6
or c, h–k 8 weeks on a HFHF diet (n = 8–10/group). a, b 14C-fructose
uptake test. After 2 weeks on the HFHF diet and a 12-h fast, wt and gt/gt
females received 14C-fructose orally and were sacrificed after 15 min and
tissue samples weremeasured for 14C radioactivity as disintegration/min/mg
(DPM) (n = 12/group). a DPM per mg of tissue in indicated tissues. b Sum
radioactivity detected in all tissues measured including and excluding the
small intestine. c qPCR analysis of themRNA levels of glucose and fructose
transporters and metabolizing enzymes in the small intestine of the gt/gt
mice relative to wt. Gene expression was studied relative to β-actin
mRNA. d Ketohexokinase activity in the small intestine of females after
4 weeks on a HFHF diet (n = 6–8/group). e Oral glucose tolerance test
(GTT). The value for 0 min was determined after a 12-h fast. f Serum
insulin levels determined from the 0-min GTT samples. g HOMA-IR
scores determined from the 0-min values. h Serum uric acid levels. i
Blood lactate levels. j Blood lactate-to-glucose ratio. k qPCR analysis of
liver mRNA levels of glucose and fructose transporters and metabolizing
enzymes in gt/gt mice relative to wt, studied relative to TATA-box-binding
protein mRNA. Data are means ± SEM. *p < 0.05, **p < 0.01,
***p < 0.001. The p value for d was calculated from log-transformed
values. b, blood; BAT, brown adipose tissue; HOMA-IR, homeostatic
model assessment-insulin resistance; KHK, ketohexokinase; s, serum;
SLC2A 1-5, solute carrier family-2 member 1-5; WAT, white adipose tissue
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mRNA level of the fructose-uptaking Slc2a2 was significantly
lower in the Hif-p4h-2gt/gt than in the WT, supporting the re-
duced hepatic 14C-fructose uptake, while there was no difference
between the genotypes in the levels of Slc2a5 or Khks (Fig. 3k).
Of note, the expression level of Slc2a2 mRNA was ~65-fold
compared Slc2a5 (data not shown), being in agreement with
the role of GLUT2 as the main hepatic fructose transporter.
HIF-P4H-2-deficient mice were protected
from obesity and retained a healthier serum lipid
profile when challenged with an HF-MCD diet
Next, the Hif-p4h-2gt/gt and WT mice were fed the HF-MCD
diet, inducing a more severe form of NAFLD than the HFHF
diet. The weight gain of the Hif-p4h-2gt/gt mice was signifi-
cantly lower than that of the WT during the 7-week diet, and
at sacrifice, they had a 22% lower body weight (Fig. 4a–c).
In agreement, theHif-p4h-2gt/gtmice had 45% less WAT than
the WT with significantly smaller adipocytes and a trend
towards lower BAT weight (Fig. 4d–f). Also, less macro-
phage aggregates were detected in their WAT (Fig. 4g).
Additionally, the Hif-p4h-2gt/gt mice retained a healthier se-
rum lipid profile than the WT, their total cholesterol level
being significantly lower (Fig. 4h), the same applying to
their glucose levels (Fig. S4). No differences in serum tri-
glyceride and FFA levels were detected between the geno-
types on this diet, either (Fig. 1i).
Hif-p4h-2gt/gt mice were protected against HF-MCD
diet–induced steatosis and liver damage
The liver weights of theHif-p4h-2gt/gtmice were > 20% lower
than those of the WT after the HF-MCD diet (Fig. 5a).
Consistently, theHif-p4h-2gt/gt livers had a significantly lower
hepatic triglyceride content (Fig. 5b) and histological scores
for steatosis severity, ~ 35% of theHif-p4h-2gt/gt livers against
~ 70% of WT scored as “very severe” (Fig. 5c). Only mild
inflammation (Fig. 5d) and fibrosis (Fig. S5a) were detected to
similar extents in both genotypes. Serum ALT and AST were
elevated to a pathological level in both genotypes, but they
were significantly ~ 30% lower in theHif-p4h-2gt/gt than in the
WT mice (Fig. 5e, f). Additionally, the serum albumin levels
were significantly higher for the Hif-p4h-2gt/gt mice than for
the WT (Fig. 5g), and the Hif-p4h-2gt/gt livers had more pro-
liferating cells than the WT (Fig. 5h) with no difference in
apoptosis (Fig. S5b), suggesting enhanced regeneration in
the Hif-p4h-2gt/gt livers. Both genotypes’ livers showed simi-
lar dispersed expression of pericentral zonation marker gluta-
mine synthetase (Fig. S5c). In agreement with less fat accu-
mulation and damage detected in the Hif-p4h-2gt/gt livers
than in the WT, the hepatic expression levels of several lipid
metabolism and oxidative stress mRNAs were lower, while
the Hif-p4h-2mRNA downregulation was similar to that on
the HFHF diet (Figs. 5i and S5d). Additionally, the levels of
all cholesterol synthesis precursors but squalene were re-
duced in the Hif-p4h-2gt/gt liver compared with that in the
Fig. 4 HIF-P4H-2-deficient mice are protected against HF-MCD diet–
induced obesity, adipose tissue inflammation, and higher cholesterol
levels. Wild-type (wt) and Hif-p4h-2gt/gt (gt/gt) females were studied
while on a 7-week high-fat, methionine-choline-deficient (HF-MCD) diet
(n = 10–12/group). a Body weight development during the 7 weeks. b
Body weight at sacrifice. c Weight gain at the end of the diet relative to
weights on the day before the diet started. d Weight of gonadal WAT. e
Cross-sectional area of WATadipocytes. Scale bar = 100 μm. fWeight of
BAT. g Number of macrophage aggregates in WAT. *Adipocytes
surrounded by macrophage aggregates. Scale bar = 100 μm. h Serum
total cholesterol, HDL cholesterol, and LDL cholesterol levels. i Serum
TG and FFA levels (n = 6–9/group). Data are means ± SEM. *p < 0.05,
**p < 0.01, ***p < 0.001. BAT, brown adipose tissue; FFA, free fatty
acids; s, serum; TG, triglycerides; WAT, white adipose tissue
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WT (Table S2), which suggests downregulated cholesterol
synthesis in the former, likely contributing to the observed
lower serum cholesterol levels (Fig. 4h). Additionally, se-
rum uric acid levels were significantly lower in theHif-p4h-
2gt/gtmice, while no differences were detected in the FGF21
levels (Fig. S5e, f). These data indicate that the Hif-p4h-2gt/
gt mice showed protection against the HF-MCD diet–
induced hepatic fat accumulation and damage compared
with the WT.
Increased heat production in the HIF-P4H-2-deficient
mice on an HF-MCD diet is associated with protection
from NAFLD
Browning of WAT has been shown to be a protective
mechanism against NAFLD in mice on MCD diet [28,
29]. Therefore, we next studied the expression of
uncoupling protein 1 (UCP1) in the WAT of the HF-
MCD diet–fed mice. Surprisingly, the Hif-p4h-2gt/gt mice
showed significantly more UCP1 expression (83.3%) than
the WT (33.3%) (Fig. 6a), verified by Western blotting
(Fig. 6b). No difference between the genotypes in BAT
UCP1 levels was detected (data not shown). In agreement,
the mRNA levels of the browning markers Ucp1, Ppara,
Pparg, Pparg2, Cebpa, Prdm16, Vegfa, Ppargc1a, Acsl1,
and Lipe were significantly upregulated in the Hif-p4h-2gt/
gt WAT relative to the WT, the downregulation of Hif-p4h-
2 mRNA being similar to that on normal chow [14]
(Fig. 6c). Since UCP1 expression relates to heat produc-
tion, we submitted the mice on the HF-MCD diet for
indirect gas calorimetry analysis, which showed signifi-
cantly increased heat production by the Hif-p4h-2gt/gt
mice compared with the WT (Fig. 6d). There was no
difference between the genotypes in physical activity,
Fig. 5 HIF-P4H-2 deficiency protects mice from HF-MCD diet–induced
fatty liver disease. Wild-type (wt) and Hif-p4h-2gt/gt (gt/gt) females were
studied while on a 7-week high-fat, methionine-choline-deficient (HF-
MCD) diet (n = 10–12/group). a Liver weight. b Hepatic triglyceride
content. c Scoring of steatosis and H&E-stained liver sections. Steatosis
grading: “Moderate” corresponds to score 2, “Severe” to 3, and “Very
severe” to 4. “Very severe” and “severe” images are representative of
scoring for wt, and “moderate” for gt/gt. Scale bar = 500 μm for × 4
and 200 μm for × 10. d Scoring of inflammation from H&E-stained liver
sections. “No” corresponds to scores 0–1 and “Yes” to 2–4. Arrows
indicate neutrophil clusters in wt. Scale bar = 100 μm. e Serum ALT
levels. f Serum AST levels. g Serum albumin levels (n = 9–10/group). h
Number of Ki67-positive proliferating cells in the liver sections. Arrows
indicate Ki67-positive cells. Scale bar = 50 μm. i qPCR analysis of liver
mRNA levels of gt/gt mice relative to wt, studied relative to TATA-box-
binding protein mRNA. a, b, e–i Data are means ± SEM. *p < 0.05,
**p < 0.01, ***p < 0.001. Alb, albumin; ALT, alanine aminotransferase;
AST, aspartate aminotransferase; CHREBP, carbohydrate-responsive el-
ement-binding protein; GPX1, glutathione peroxidase 1; LPIN, lipin;
MTTP, microsomal triglyceride transfer protein; PPARg2, peroxisome
proliferator–activated receptor gamma 2; s, serum; TG, triglycerides
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respiratory exchange ratio, or food intake (Fig. 6e–g), but
an increase in water intake was observed in the Hif-p4h-
2gt/gt mice (Fig. 6h). These differences were not observed
in previous measurements on normal chow [14], neither in
the baseline measurements preceding the HF-MCD diet
feeding, and no browning was detected in either genotype
on the HFHF diet (data not shown). These data suggest
that the Hif-p4h-2gt/gt mice used advanced browning of
WAT as a mechanism of protection against HF-MCD
diet–induced NAFLD.
Fig. 6 Heat production via UCP1 activation in the WAT is associated
with protection from HF-MCD diet–induced NAFLD in HIF-P4H-2-
deficient mice. Wild-type (wt) and Hif-p4h-2gt/gt (gt/gt) females were
studied while on a 7-week high-fat, methionine-choline-deficient (HF-
MCD) diet. a Scoring of UCP1-stained WAT sections. “No” corresponds
to < 5% of UCP1 staining/field and “Yes” to 5–25% (n = 10–12/group).
Images are representative of scoring for wt. Scale bar = 500 μm for × 4
and 200 μm for × 10. bWestern blotting and densitometric quantification
of WAT UCP1 levels (n = 3–4/group.). β-Actin was used as a loading
control. c qPCR analysis of the mRNA levels of browning markers in the
WAT of the gt/gt mice relative to wt (n = 10–12/group). Gene expression
was studied relative to β-actin mRNA. d–h Mice were analyzed in
metabolic home cages for the last week of the diet (n = 7–8/group). d
Heat production and AUC. e Total physical activity and AUC. f
Respiratory exchange ratio (VCO2/VO2/kg) and AUC. g Food intake
and AUC. h Water intake and AUC. b–h Data are means ± SEM.
*p < 0.05, **p < 0.01, ***p < 0.001. ACSL1, acyl-CoA synthetase
long-chain family member 1; AUC, area under the curve; CEBPA,
CCAAT-enhancer-binding protein alpha; CIDEA, cell death–inducing
DFFA-like effector A; LIPE, hormone-sensitive lipase; PPAR a/g, perox-
isome proliferator–activated receptor alpha/gamma; PPARGC1A,
PPARg coactivator-1 alpha; PRDM16, PR/SET domain-16; UCP1,
uncoupling protein 1; VEGFA, vascular endothelial growth factor A;
WAT, white adipose tissue
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Fig. 7 Pharmacological inhibition of HIF-P4Hs ameliorates diet-induced
obesity, metabolic dysfunction, and liver damage. Wild-type (wt) females
were fed a high-fat, high-fructose (HFHF) diet for e 4 or a–d, f–l 6 weeks
or a high-fat, methionine-choline-deficient (HF-MCD) diet for m–s
3 weeks and simultaneously given vehicle (VEH) or 60 mg/kg of FG-
4497 (FG) on days 1, 3, and 5 of each week (n = 8–10/group). aWestern
blot analysis of hepatic HIF1α and HIF2α protein levels. β-Actin was
used as a loading control. bBlood hemoglobin levels. cWeight gain at the
end of the diet relative to weights on the day before the diet started. d
Weight of gonadal WAT. e Oral glucose tolerance test. The value for
0 min was determined after a 12-h fast. f Liver weight. g Scoring of
hepatic steatosis. Steatosis grading: “None” corresponds to scores 0–2,
“Moderate” to 3, and “Severe” to 4. h Scoring of liver inflammation.
“No” corresponds to score 0 and “Yes” to 1–2. i qPCR analysis of liver
mRNA levels of FG-treatedmice relative to VEH-treated, studied relative
to TATA-box-binding protein mRNA. j Serum ALT levels. k Blood lac-
tate levels. l Serum uric acid levels.mWeight gain at the end of the HF-
MCD diet relative to weights on the day before the diet started. n Serum
total cholesterol, HDL cholesterol, and LDL cholesterol levels. o Liver
weight. p Scoring of hepatic steatosis. Steatosis grading: “Moderate”
corresponds to score 2 and “Severe” to 3. q Serum ALT levels. r
Scoring of UCP1-stained WAT sections. “No” corresponds to < 5% of
UCP1 staining/field and “Yes” to 5–25%. Images are representative of
scoring for the VEH group. Scale bar = 200 μm. s qPCR analysis ofWAT
mRNA levels of FG-treated mice relative to VEH-treated group, studied
relative to peptidylprolyl isomerase A mRNA. b–f, i–o, q, s Data are
means ± SEM. *p ≤ 0.05, **p < 0.01, ***p < 0.001. ACSL1, acyl-CoA
synthetase long-chain family member 1; ALT, alanine aminotransferase;
b, blood; CEBPA, CCAAT-enhancer-binding protein alpha; CHREBP,
carbohydrate-responsive element-binding protein; DGAT1, diacylglycer-
ol o-acyltransferase 1; FASN, fatty acid synthase; GPAM, mitochondrial
glycerol-3-phosphate acyltransferase; LPIN, lipin; PPAR a/g, peroxisome
proliferator–activated receptor alpha/gamma; PRDM16, PR/SET
domain-16; s, serum; SCD1, stearoyl-CoA desaturase 1; SLC2A2, solute
carrier family-2 member 2; SREBF1c, sterol regulatory element-binding
protein 1c; UCP-1, uncoupling protein 1; VEGFA, vascular endothelial
growth factor A; WAT, white adipose tissue
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diet-induced obesity, metabolic dysfunction,
and NAFLD
WT mice were fed the HFHF diet for 6 weeks and simulta-
neously treated with a pharmacological pan-HIF-P4H inhibi-
tor FG-4497 or vehicle. The FG-4497 treatment stabilized
HIF1α and HIF2α in the livers (Fig. 7a) and elevated the
blood hemoglobin levels (Fig. 7b). The FG-4497-treated mice
did not gain weight (Fig. 7c) and had less WAT (Fig. 7d) than
the vehicle-treated mice. They also showed a trend towards a
better glucose tolerance (Fig. 7e). However, no significant
differences in liver weight or steatosis were detected between
groups (Fig. 7f, g), liver inflammation being detected only in
the vehicle-treated group (Fig. 7h). The inability of the FG-
4497 treatment to protect against steatosis compared with the
Hif-p4h-2gt/gt livers associated with only a few lipogenic
mRNAs and Slc2a2 being downregulated, and conversely
with Pparg mRNA upregulation (Fig. 7i). Although not sig-
nificant, the serum ALT levels were ~ 40% lower in the FG-
4497 group (Fig. 7j), indicating less liver damage, possibly
stemming from lower intake of fructose due to Slc2a2 down-
regulation. Moreover, systemic levels of lactate and uric acid
were significantly lower in the FG-4497-treated group
(Fig. 7k, l). In conclusion, the FG-4497 treatment stabilized
HIF, protecting from the HFHF diet–induced obesity and he-
patic inflammation, but not from steatosis.
We next fed WT mice the HF-MCD diet for 3 weeks with
simultaneous FG-4497 or vehicle treatment. The FG-4497
treatment was protected from weight gain (Fig. 7m) and the
mice had a healthier serum lipid profile than the vehicle-
treated group (Fig. 7n), but no difference in liver weight or
steatosis was detected between the groups (Fig. 7o, p).
Nevertheless, the FG-4497-treated mice had lower serum
ALT levels (Fig. 7q). Lastly, similar expression levels of
WAT UCP1 and browning marker mRNAs were detected in
both groups (Fig. 7r, s). In conclusion, the FG-4497 treatment
on the HF-MCD diet was protected from obesity, hypercho-
lesterolemia, and liver damage, but could not induce browning
of WAT to the extent seen in the Hif-p4h-2gt/gt mice and thus,
was unable to protect against steatosis.
Discussion
Obesity andWAT function play key roles in the progression of
NAFLD, since obesity and IR induce adipose tissue lipolysis
and the liver then accumulates circulating FAs in a
concentration-dependent manner [30]. Fructose contributes
to NAFLD by providing a substrate for increased FA synthesis
and activating hepatic de novo lipogenesis, which it promotes
directly by upregulating SREBP1c [31], and indirectly by uric
acid production, which reduces mitochondrial β-oxidation
resulting in oxidative stress, hepatic IR, and endoplasmic re-
ticulum (ER) stress [32, 33]. Absorbed fructose is transported
via the portal vein, thus reaching the liver in higher concen-
trations than the other tissues.
The roles of HIFs and HIF-P4Hs in NAFLD are complex
and not yet fully understood. The data available until this
study is mainly from liver/hepatocyte-specific settings and
suggest that stabilization of HIF2α, or simultaneous inhibition
of all HIF-P4Hs, promotes NAFLD while restricting the inhi-
bition to selected isoenzymes may have beneficial effects [14,
34–38]. We have reported earlier that normal chow-fed Hif-
p4h-2gt/gt mice have hepatic stabilization of HIF2α but not of
HIF1α with upregulation of Irs2 and downregulation of
Srebf1cmRNA, resulting in lower acetyl-CoA levels, reduced
de novo lipogenesis, and lower IR than the WT [14, 17].
Furthermore, we recently showed that mouse embryonic fi-
broblasts isolated from Hif-p4h-2gt/gt mice show ~ 50% re-
duced ATP production compared with WT cells, likely
resulting in the baseline differences in adiposity [14, 18]. We
now show that Hif-p4h-2gt/gt mice were able to resist weight
gain and adiposity on a HFHF diet and had less hepatic
steatosis and liver damage and no inflammation or fibrosis.
These features associated with downregulation of lipogenic
mRNAs, lower levels of hepatic acetyl-CoA and serum insu-
lin, and better glucose tolerance. Moreover, differences in
fructose metabolism in favor of the Hif-p4h-2gt/gt mice were
detected, including 20–33% less fructose found in the liver,
kidney, and serum than in the WT, and lower levels of serum
uric acid and lactate. Interestingly, the mRNA levels and en-
zymatic activity of KHKs, which are responsible for the cleav-
age of fructose, were upregulated in the small intestine of the
Hif-p4h-2gt/gt mice. The small intestine is the major site of
fructose metabolism when ingested in low doses, whereas
fructose spills over into the liver at high doses [26]. Our data
suggest that inhibition of HIF-P4H-2 increases the capacity of
the intestine to metabolize high doses of dietary fructose and
therefore provides protection from its spillover into the liver
and other tissues.
Moreover, the Hif-p4h-2gt/gt mice on a HFHF diet
expressed hepatic mRNAs for Pnpla2, Pnpla3, and
Cyp2e1 at lower levels than the WT. Inhibition of the
adipose ligase PNPLA2 has been associated with protec-
tion against ER stress in mice [39, 40], while activating
genetic variants in PNPLA3 are associated with human
NAFLD [41]. Moreover, increased expression of hepatic
CYP2E1, which carries out the omega-hydroxylation of
FAs, has been associated with NASH in mice and humans
[42].
Additionally, the Hif-p4h-2gt/gt mice on the HF-MCD diet
had lessWAT, and interestingly, they showed improved brow-
ning of WAT, which was associated with increased heat pro-
duction. This likely contributed to less hepatic steatosis in the
Hif-p4h-2gt/gt mice, as WAT browning protecting against
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NAFLD has been reported on an MCD diet [28, 29].
However, this is the first report associating HIF-P4H inhibi-
tionwith induced browning ofWATand increased thermogen-
esis, while earlier reports associate environmental hypoxia
with HIF pathway activation and WAT browning [43, 44].
This likely involves the observed upregulation of adipose tis-
sue PPARγ, which is a HIF target gene and essential in WAT
browning [45–47].
Even though fructose is also required to develop liver
injury on the HF-MCD diet, which contains sucrose [48],
this diet additionally prevents hepatic VLDL export fur-
ther compromising liver metabolism. This likely explains
the lower degree of downregulation of hepatic lipid me-
tabolism genes in the Hif-p4h-2gt/gt mice on the HF-MCD
diet compared with the HFHF diet.
NAFLD treatment is currently based on diet and exercise,
while several therapeutics are being used with varying results.
We show here that beneficial effects could be obtained with
HIF-P4H-2 inhibition, as its genetic deficiency counteracted
the symptoms of NAFLD. However, treatment with pan-HIF-
P4H inhibitor was unable to reduce steatosis, as it demonstrat-
ed reduced ability to downregulate hepatic lipogenic gene
expression in the HFHF diet and failure to significantly induce
WAT browning in the HF-MCD diet. These data suggest that
treatment of NAFLD by HIF-P4H inhibition should target
only isoenzyme 2. This is supported by previous studies that
associate the knockout of all HIF-P4Hs with steatosis, while
the presence of a single HIF-P4H-1 or HIF-P4H-3 allele min-
imizes steatosis [49]. In conclusion, our findings demonstrate
important underlying mechanisms of HIF-P4H-2 interference
involving organ crosstalk in the pathogenesis of NAFLD,
which offers potential for developing HIF-P4H-2 inhibitors
for its treatment.
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